133 related articles for article (PubMed ID: 37828918)
1. Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.
Shah M; Woo HG
Front Mol Biosci; 2023; 10():1236617. PubMed ID: 37828918
[TBL] [Abstract][Full Text] [Related]
2. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.
Ju B; Fan Q; Liu C; Shen S; Wang M; Guo H; Zhou B; Ge X; Zhang Z
Cell Rep; 2023 Jun; 42(6):112532. PubMed ID: 37219999
[TBL] [Abstract][Full Text] [Related]
3. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
4. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
Touret F; Giraud E; Bourret J; Donati F; Tran-Rajau J; Chiaravalli J; Lemoine F; Agou F; Simon-Lorière E; van der Werf S; de Lamballerie X
iScience; 2023 Apr; 26(4):106413. PubMed ID: 36968074
[TBL] [Abstract][Full Text] [Related]
5. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
[TBL] [Abstract][Full Text] [Related]
6. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
Bruel T; Vrignaud LL; Porrot F; Staropoli I; Planas D; Guivel-Benhassine F; Puech J; Prot M; Munier S; Henry-Bolland W; Soulié C; Zafilaza K; Lusivika-Nzinga C; Meledge ML; Dorival C; Molino D; Péré H; Yordanov Y; Simon-Lorière E; Veyer D; Carrat F; Schwartz O; Marcelin AG; Martin-Blondel G;
medRxiv; 2023 May; ():. PubMed ID: 37398037
[TBL] [Abstract][Full Text] [Related]
8. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
9. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
[TBL] [Abstract][Full Text] [Related]
10. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
11. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
[TBL] [Abstract][Full Text] [Related]
13. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
14. Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.
Entzminger KC; Fleming JK; Entzminger PD; Espinosa LY; Samadi A; Hiramoto Y; Okumura SCJ; Maruyama T
Antib Ther; 2023 Apr; 6(2):108-118. PubMed ID: 37324547
[TBL] [Abstract][Full Text] [Related]
15. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
[TBL] [Abstract][Full Text] [Related]
16. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge.
Liu Q; Zhao H; Li Z; Zhang Z; Huang R; Gu M; Zhuang K; Xiong Q; Chen X; Yu W; Qian S; Zhang Y; Tan X; Zhang M; Yu F; Guo M; Huang Z; Wang X; Xiang W; Wu B; Mei F; Cai K; Zhou L; Zhou L; Wu Y; Yan H; Cao S; Lan K; Chen Y
Signal Transduct Target Ther; 2023 Sep; 8(1):347. PubMed ID: 37704615
[TBL] [Abstract][Full Text] [Related]
18. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Driouich JS; Bernadin O; Touret F; de Lamballerie X; Nougairède A
Antiviral Res; 2023 Jul; 215():105638. PubMed ID: 37207822
[TBL] [Abstract][Full Text] [Related]
19. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi A; Bloom JD; Chu HY; Lee KK; Overbaugh J
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2220948120. PubMed ID: 37253011
[TBL] [Abstract][Full Text] [Related]
20. Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants.
Alcantara MC; Higuchi Y; Kirita Y; Matoba S; Hoshino A
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
